These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38970840)

  • 1. A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium.
    Lenti MV; Ribaldone DG; Borrelli de Andreis F; Vernero M; Barberio B; De Ruvo M; Savarino EV; Kav T; Blesl A; Franzoi M; Gröchenig HP; Pugliese D; Ianiro G; Porcari S; Cammarota G; Gasbarrini A; Spagnuolo R; Ellul P; Foteinogiannopoulou K; Koutroubakis I; Argyriou K; Cappello M; Jauregui-Amezaga A; Demarzo MG; Silvestris N; Armuzzi A; Sottotetti F; Bertani L; Festa S; Eder P; Pedrazzoli P; Lasagna A; Vanoli A; Gambini G; Santacroce G; Rossi CM; Delliponti M; Klersy C; Corazza GR; Di Sabatino A;
    ESMO Open; 2024 Jul; 9(7):103632. PubMed ID: 38970840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis.
    Mooradian MJ; Wang DY; Coromilas A; Lumish M; Chen T; Giobbie-Hurder A; Johnson DB; Sullivan RJ; Dougan M
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication-specific variations in morphological patterns of injury in immune check-point inhibitor-associated colitis.
    Isidro RA; Ruan AB; Gannarapu S; Raj D; Rahma O; Grover S; Srivastava A
    Histopathology; 2021 Mar; 78(4):532-541. PubMed ID: 32931028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Follow-up biopsies in gastrointestinal immune checkpoint inhibitor toxicity may show markedly different inflammatory patterns than initial injury.
    Tomm NK; Szczepanski JM; Fang JM; Choi WT; Xue Y; Setia N; Karamchandani DM; Cheng JY; Westerhoff M
    Hum Pathol; 2024 Jun; 148():60-65. PubMed ID: 38734079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P067 Immune Checkpoint Inhibitor Colitis in a Community-Based Hospital System.
    Rampersad A; Abrams G; Bauer C
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S17-S18. PubMed ID: 37461984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
    Burisch J
    Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma.
    Favara DM; Spain L; Au L; Clark J; Daniels E; Diem S; Chauhan D; Turajlic S; Powell N; Larkin JM; Yousaf N
    ESMO Open; 2020 Jul; 5(4):. PubMed ID: 32641348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?
    Cheung VTF; Gupta T; Olsson-Brown A; Subramanian S; Sasson SC; Heseltine J; Fryer E; Collantes E; Sacco JJ; Pirmohamed M; Simmons A; Klenerman P; Tuthill M; Protheroe AS; Chitnis M; Fairfax BP; Payne MJ; Middleton MR; Brain O
    Br J Cancer; 2020 Jul; 123(2):207-215. PubMed ID: 32418993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of immune checkpoint inhibitor in patients with cancer and pre-existing inflammatory bowel disease: Recommendations from the GETAID.
    Amiot A; Laharie D; Malamut G; Serrero M; Poullenot F;
    Dig Liver Dis; 2022 Sep; 54(9):1162-1167. PubMed ID: 35842365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitor-induced diarrhea: Clinicopathological study of 11 patients.
    Yanai S; Nakamura S; Kawasaki K; Toya Y; Akasaka R; Oizumi T; Ishida K; Sugai T; Matsumoto T
    Dig Endosc; 2020 May; 32(4):616-620. PubMed ID: 31595568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study.
    Sleiman J; Wei W; Shah R; Faisal MS; Philpott J; Funchain P
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34158318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-integrin αvβ6 autoantibodies are a potential biomarker for ulcerative colitis-like immune checkpoint inhibitor-induced colitis.
    Yokode M; Shiokawa M; Kawakami H; Kuwada T; Nishikawa Y; Muramoto Y; Kitamoto H; Okabe M; Yamazaki H; Okamoto N; Morita T; Ohno K; Nakanishi R; Takimoto I; Yasuda M; Chikugo K; Matsumoto S; Yoshida H; Ota S; Nakamura T; Okada H; Hirano T; Kakiuchi N; Matsumori T; Yamamoto S; Uza N; Ooi M; Kodama Y; Chiba T; Hayashi H; Seno H
    Br J Cancer; 2024 May; 130(9):1552-1560. PubMed ID: 38461170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course.
    Haryal A; Townsend MJ; Baskaran V; Srivoleti P; Giobbie-Hurder A; Sack JS; Isidro RA; LeBoeuf NR; Buchbinder EI; Hodi FS; Grover S
    Cancer; 2023 Feb; 129(3):367-375. PubMed ID: 36377339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study.
    Atia O; Shavit-Brunschwig Z; Mould DR; Stein R; Matar M; Aloi M; Ledder O; Focht G; Urlep D; Hyams J; Broide E; Weiss B; Levine J; Russell RK; Turner D
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):31-42. PubMed ID: 36306803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
    Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
    JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fecal transplantation for treatment of inflammatory bowel disease.
    Imdad A; Nicholson MR; Tanner-Smith EE; Zackular JP; Gomez-Duarte OG; Beaulieu DB; Acra S
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012774. PubMed ID: 30480772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
    Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and Validation of Diagnostic Criteria for IBD Subtypes Including IBD-unclassified in Children: a Multicentre Study From the Pediatric IBD Porto Group of ESPGHAN.
    Birimberg-Schwartz L; Zucker DM; Akriv A; Cucchiara S; Cameron FL; Wilson DC; Lazowska I; Yianni L; Paul SP; Romano C; Kolacek S; Buderus S; Pærregaard A; Russell RK; Escher JC; Turner D;
    J Crohns Colitis; 2017 Sep; 11(9):1078-1084. PubMed ID: 28430891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.